Shots:Sanofi has licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases under their Dec 2019 dealAs per the deal, Nurix used its DEL-AI platform to develop E3 ligase-targeting degraders, with Sanofi having rights to license them. Nurix can co-develop & co-promote up to 2 US products, sharing US…